Biomol.com #2832A

KINASE INHIBITORS

PLATE	COMPOUND NAME OR ID NUMBER	M.W.	TARGET	uM	LUC-1st	LUC-2nd
B1	PD-98059	267.3	only inhibits acti	10	163%	101%
B2	U-0126	380.5	both active and i	10	121%	41%
B3	SB-203580	377.4	p38 MAPK	10	109%	35%
B4	H-7	364.3	PKA, PKG, MLC	10	57%	20%
B5	H-9	324.3	PKA, PKG, MLC	10	89%	18%
B6	Staurosporine	466.5	Pan-specific	0.01	113%	40%
B7	AG-494	280.3	EGFRK, PDGFF	10	92%	35%
B8	AG-825	397.5	HER1-2	10	94%	36%
B9	Lavendustin A	381.4	EGFRK	10	89%	47%
B10	RG-14620	274.1	EGFRK	10	101%	56%
B11	Tyrphostin 23	186.1	EGFRK	10	108%	58%
B12	Tyrphostin 25	202.1	EGFRK	10	115%	172%
C1	Tyrphostin 46	204.2	EGFRK, PDGFI	10	132%	116%
C2	Tyrphostin 47	220.2	EGFRK	10	129%	54%
C3	Tyrphostin 51	268.2	EGFRK	10	107%	31%
C4	Tyrphostin 1	184.2	Negative control	10	109%	23%
C5	Tyrphostin AG 1288	231.2	Tyrosine kinases	10	103%	19%
C6	Tyrphostin AG 1478	315.8	EGFRK	10	80%	16%
C7	Tyrphostin AG 1295	234.3	Tyrosine kinases	10	90%	36%
C8	Tyrphostin 9	282.4	PDGFRK	1	17%	0%
C9	HNMPA (Hydroxy-2-naphthalenylmethyl	238.2	IRK (insulin rece	10	107%	37%
C10	Damnacanthal	282.3	p56 lck	1	122%	31%
C11	Piceatannol	244.3	Syk	10	102%	83%
C12	PP1	281.4	Src family	10	99%	198%
D1	AG-490	294.3	JAK-2	1	142%	122%
D2	AG-126	215.2	IRAK	10	124%	94%
D3	AG-370	259.3	PDGFRK	10	128%	54%
D4	AG-879	316.5	NGFRK	10	11%	0%
D5	LY 294002	307.4	PI 3-K	10	57%	5%
D6	Wortmannin	428.4	PI 3-K	10	87%	25%
D7	GF 109203X	412.5	PKC	10	88%	25%
D8	Hypericin	504.4	PKC	1	84%	19%
D9	Ro 31-8220	553.7	PKC	1	105%	28%
D10	Sphingosine	299.5	PKC	10	88%	39%
D11	H-89	519.2	PKA	10	97%	52%
D12	H-8	338.3	PKA, PKG	10	86%	43%
E1	HA-1004	329.8	PKA, PKG	10	123%	80%
E2	HA-1077	327.8	PKA, PKG	10	92%	50%
E3	HDBA (2-Hydroxy-5-(2,5-dihydroxybenz	275.3	EGFRK, CaMK	10	100%	48%
E4	KN-62	721.9	CaMK II	1	101%	28%
E5	KN-93	501	CaMK II	10	87%	25%
E6	ML-7	452.7	MLCK	10	49%	31%
E7	ML-9	361.3	MLCK	0.5	90%	33%
E8	2-Aminopurine	135.1	p58 PITSLRE be	10	101%	28%
E9	N9-Isopropyl-olomoucine	326.4	CDK	10	61%	15%
E10	Olomoucine	298.3	CDK	10	84%	19%

E11	iso-Olomoucine	298.4	Negative control	10	95%	40%
E12	Roscovitine	354.5	CDK	10	42%	20%
F1	5-Iodotubercidin	392.2	ERK2, adenosin	0.5	80%	27%
F2	LFM-A13	360	BTK	10	103%	38%
F3	SB-202190	331.3	p38 MAPK	10	104%	52%
F4	PP2	301.8	Src family	10	95%	44%
F5	ZM 336372	389.4	cRAF	10	90%	39%
F6	SU 4312	264.3	Flk1	10	98%	42%
F7	AG-1296	266.3	PDGFRK	10	102%	29%
F8	GW 5074	520.9	cRAF	1	90%	35%
F9	Palmitoyl-DL-carnitine Cl	436.1	PKC	1	85%	30%
F10	Rottlerin	516.6	PKC delta	1	94%	21%
F11	Genistein	270.2	Tyrosine Kinase	10	107%	25%
F12	Daidzein	254.2	Negative control	10	100%	127%
G1	Erbstatin analog	194	EGFRK	1	104%	103%
G2	Quercetin dihydrate	338.3	PI 3-K	1	102%	46%
G3	SU1498	390.5	Flk1	10	106%	37%
G4	ZM 449829	182.2	JAK-3	10	95%	44%
G5	BAY 11-7082	207.3	IKK pathway	10	76%	33%
G6	DRB (5,6-Dichloro-1-β-D-ribofuranos	319.1	CK II	10	54%	5%
G7	HBDDE (2,2',3,3',4,4'-Hexahydroxy-1,1'	338.4	PKC alpha, PKC	10	77%	39%
G8	SP 600125	220.2	JNK	10	97%	30%
G9	Indirubin	262	GSK-3beta, CDI	10	80%	36%
G10	Indirubin-3'-monoxime	277.3	GSK-3beta	10	96%	22%
G11	Y-27632	338.3	ROCK (Rho-ass	10	129%	40%
G12	Kenpaullone	327.2	GSK-3beta	10	105%	109%
H1	Terreic acid	154.1	BTK	10	80%	146%
H2	Triciribine	320.3	Akt signaling pat	10	78%	83%
H3	BML-257	326.4	Akt	10	76%	34%
H4	SC-514	224.3	IKK2	10	88%	29%
H5	BML-259	260.4	Cdk5/p25	10	79%	44%
H6	Apigenin	270.2	CK-II	10	69%	7%
H7	BML-265 (Erlotinib analog)	305.4	EGFRK	10	53%	41%
H8	Rapamycin	914.2	mTOR	10	57%	25%